Dexcom Eyes US FDA Clearance For 15-Day CGM, But Insurance Coverage Remains Uncertain

Upgrade could boost Dexcom’s competitive positioning against Abbott’s Libre 3 Plus.

 
• By Shubham Singh
The new device is expected to enhance patient experience by extending wear time beyond its current 10-day G7 sensor.

More from Business

More from Policy & Regulation